AMAG - AMAG Pharmaceuticals, Inc.
| Previous Close | 9.00 |
| Open | 8.93 |
| Bid | 8.50 x 900 |
| Ask | 10.00 x 2200 |
| Day's Range | 8.60 - 9.00 |
| 52 Week Range | 7.81 - 26.10 |
| Volume | 868,224 |
| Avg. Volume | 899,980 |
| Market Cap | 295.123M |
| Beta (3Y Monthly) | 0.40 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.88 |
| Earnings Date | Jul 31, 2019 - Aug 5, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.14 |
- Simply Wall St.•12 days ago
Calculating The Intrinsic Value Of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)
How far off is AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) from its intrinsic value? Using the most recent financial...
- Zacks•17 days ago
Alexion's Ultomiris Receives EU Approval for PNH in Adults
Alexion (ALXN) obtains approval for its long-acting C5 complement inhibitor, Ultomiris, in Europe for PNH in adults.
- GuruFocus.com•23 days ago
Largest Insider Trades of the Week
Insiders delve into Sunrun, dump shares of RealPage
- Insider Monkey•24 days ago
Here’s What Hedge Funds Think About AMAG Pharmaceuticals, Inc. (AMAG)
Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]
- Zacks•25 days ago
Biotech Stock Roundup: Vertex, AMAG Drugs Get FDA Nod, Conatus Study Fails & More
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
- Motley Fool•26 days ago
Why Palatin Technologies Stock Dropped as Much as 21.5% Today
A high-profile analyst questioned the company's recent FDA approval.
- American City Business Journals•26 days ago
How Raleigh's Sprout can benefit from FDA's approval of another female sexual disorder drug
The FDA’s recent approval of a second drug to treat a female sexual disorder means competition for one Triangle drug-maker, but also the growth of an industry its CEO hopes will drive success for her firm.
- Zacks•27 days ago
AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire
AMAG Pharmaceuticals (AMAG) announces that the FDA has approved Vyleesi to treat acquired, generalized hypoactive sexual desire disorder in premenopausal women.
- TheStreet.com•27 days ago
Palatin Jumps Then Pulls Back After FDA Clears Sexual-Desire Drug for Women
on Monday jumped and then pulled back after the biopharma was cleared by the U.S. Food and Drug Administration to market a drug to treat weakened sexual desire in women. Palatin shares closed down 9.7% at $1.21. The FDA cleared Vyleesi, a treatment for premenopausal women with acquired generalized hypoactive sexual desire disorder, Palatin said.
- Barrons.com•27 days ago
Another Women’s Libido Drug, Vyleesi, Won FDA Approval. Stock Investors Aren’t Happy.
It has been a roller-coaster day on the market for the two companies behind Vyleesi, an injection that received Food and Drug Administration approval last week to treat low sex drive in women. The drug’s approval received significant news coverage, and much of it focused on the controversy that surrounded the other drug approved for low sex drive in women, Addyi, which has struggled on the market and drawn criticism for its potential side effects. The approval of Addyi, marketed by Sprout Pharmaceuticals, drew significant attention in 2015, and led to the $1 billion acquisition of Sprout by (BHC) now (BHC) (BHC).
- MarketWatch•27 days ago
Palatin's stock rockets after FDA OK to market sexual desire disorder treatment
Shares of Palatin Technologies Inc. rocketed 27% in very active premarket trading Monday, after a positive Food and Drug Administration decision on AMAG Pharmaceuticals Inc.'s treatment for hypoactive sexual desire disorder (HSDD) triggered a $60 million milestone payment. Trading volume was over 2.9 million shares, making Palatin's stock the most actively traded ahead of the open. The FDA granted marketing approval for AMAG's new drug application (NDA) for Vyleesi, which was developed by Palatin. AMAG's stock surged 8.1% ahead of the open. The company expects to receive the milestone payment in July. Based on the license agreement with AMAG, Palatin is also entitled to receive royalties on sales, ranging from high single-digit to low double-digit percentage ranges, and other milestone payments based on escalating annual sales thresholds. Palatin's stock has rallied 23% over the past 12 months and AMAG shares have tumbled 59%, while the S&P 500 has gained 7.1%.
- Benzinga•29 days ago
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Readouts And IPOs
Biotech stocks came made upward moves last week after a rangebound period. Among big pharma companies, Merck & Co., Inc. (NYSE: MRK ) was a standout gainer, notching up 52-week highs in successive sessions, ...
- MarketWatch•last month
AMAG stock rallies on FDA approval for drug to increase women's sex drive
The U.S. Food and Drug Administration late Friday approved a drug to treat low libido in women, and shares of the company slated to market the medication, AMAG Pharmaceuticals Inc. , shot more than 16% in the extended session. The drug, Vyleesi, is aimed at premenopausal women in whom low sex drive causes distress. It comes in an auto-injecting pen that can be used ahead of sexual activity. Vyleesi is expected to be commercially available in September. AMAG licensed Vyleesi from Palatin Technologies Inc. and under the terms of their agreement the FDA approval triggers a $60 million payment to Palatin, plus tiered royalties tied to sales milestones. Shares of Palatin rallied 30% in the extended session. Both stocks ended the regular trading day more than 4% higher.
- American City Business Journals•last month
Amag’s plan to bypass female libido drug pitfalls? Social media.
Amag Pharmaceuticals Inc. has received regulatory approval to begin selling Vyleesi, a drug designed to address hypoactive sexual disorder, a condition in which causes low sexual desire and distress in an estimated one in 10 women.
- GlobeNewswire•last month
AMAG Pharmaceuticals Announces FDA Approval of Vyleesi™ (Bremelanotide Injection) for Acquired, Generalized Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
AMAG Pharmaceuticals, Inc. (AMAG) announced today that the U.S. Food and Drug Administration (FDA) has approved Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist, to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by low sexual desire that causes distress or interpersonal difficulty and is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.
- Zacks•last month
All You Need to Know About AMAG Pharmaceuticals (AMAG) Rating Upgrade to Buy
AMAG Pharmaceuticals (AMAG) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•last month
TherapeuticsMD Enters Agreement to Market Drugs Outside US
TherapeuticsMD (TXMD) grants exclusive commercialization rights to its drugs, Bijuva and Imvexxy, to Theramex in ex-U.S. markets except for Canada and Israel.
- Zacks•last month
AMAG Pharmaceuticals (AMAG) Down 8.9% Since Last Earnings Report: Can It Rebound?
AMAG Pharmaceuticals (AMAG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- TheStreet.com•2 months ago
AMAG Pharmaceuticals Could Be Cut in Half Even From Here - Avoid
The daily On-Balance-Volume (OBV) has been in a downtrend the past 12 months and the Moving Average Convergence Divergence (MACD) oscillator has spent most of the past year below the zero line in bear territory. In this long-term weekly chart of AMAG, below, we can see the price action all the way back to 1987. The weekly OBV line is bearish and so is the MACD oscillator.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference
WALTHAM, Mass., May 29, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the.
- Simply Wall St.•2 months ago
Is AMAG Pharmaceuticals, Inc.'s (NASDAQ:AMAG) Balance Sheet A Threat To Its Future?
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) is a small-cap stock with a market capitalization of US$349m. While investors...
- Zacks•2 months ago
New Strong Sell Stocks for May 20th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Host Analyst Day on May 22, 2019 in New York
WALTHAM, Mass., May 17, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 22,.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of AMAG earnings conference call or presentation 7-May-19 12:00pm GMT
Q1 2019 AMAG Pharmaceuticals Inc Earnings Call
- Zacks•2 months ago
New Strong Sell Stocks for May 10th
Here are 5 stocks added to the Zacks Rank 5 (Strong Sell) List today.
